NAMSA (ARCHIMED) Acquires Clinlogix

NAMSA Acquires Syntactx

January 5, 2021

Healthcare Services

NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

ArchiMed Acquires Majority Stake in NAMSA

September 1, 2020

Healthcare Services

ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.

NAMSA Acquires SUAZIO

March 27, 2023

Healthcare Services

ARCHIMED-funded NAMSA has acquired SUAZIO, a Belgium-headquartered, data-driven life sciences and MedTech marketing and research consultancy. The add-on expands NAMSA's strategic consulting, market research and commercialization capabilities across medical devices and IVD markets; SUAZIO's founder reinvested proceeds and will continue to lead its consultancy services.

NAMSA Acquires American Preclinical Services (APS)

March 2, 2021

Medical Devices

Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.

NAMSA Acquires WuXi AppTec U.S. Medical Device Testing Operations

January 17, 2025

Healthcare Services

NAMSA, an ARCHIMED-backed MedTech testing and clinical consulting firm, has acquired WuXi AppTec’s U.S. medical device testing operations (facilities in Minnesota and Georgia). The add-on expands NAMSA’s laboratory capacity and scientific capabilities across biocompatibility, microbiology, preclinical and extractables & leachables testing to better serve medical device manufacturers.

NAMSA Acquires Perfectus Biomed Group

October 4, 2022

Medical Devices

NAMSA, a global MedTech CRO headquartered in Toledo, Ohio, has acquired Perfectus Biomed Group, a UK-based microbiological testing laboratory headquartered in Cheshire. The acquisition expands NAMSA's European laboratory services and deepens its microbiological testing and biofilm expertise to better support medical device clients; terms were not disclosed.